NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

CTLA4(細胞傷害性T淋巴球相關蛋白質4)抑制劑的全球市場:2019年∼2023年

CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market by Type and Geography - Global Forecast and Analysis 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 910217
出版日期 內容資訊 英文 116 Pages
訂單完成後即時交付
價格
CTLA4(細胞傷害性T淋巴球相關蛋白質4)抑制劑的全球市場:2019年∼2023年 CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market by Type and Geography - Global Forecast and Analysis 2019-2023
出版日期: 2019年09月03日內容資訊: 英文 116 Pages
簡介

全球的CTLA4(細胞傷害性T淋巴球-淋巴球相關蛋白質4)抑制劑市場上,CTLA4抑制劑的高標的親和性特異性,聯合治療日益流行,策略性聯盟等成為成長促進因素,在預測期間內預計將以9%以上的年複合成長率擴大。但,由於已批准治療方法的缺乏,替代品的可得性,嚴格法規等要素,可能妨礙在預測期間內CTLA4抑制劑產業的成長。

本報告提供全球CTLA4(細胞傷害性T淋巴球相關蛋白質4)抑制劑市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各類型

  • 市場區隔:各類型
  • 比較:各類型市場規模及預測(2018年∼2023年)
  • 單劑療法
  • 聯合治療
  • 市場機會:各類型

第7章 客戶形勢

第8章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第9章 決策架構

第10章 成長要素與課題

  • 市場成長要素
  • 市場課題

第11章 市場趨勢

  • 研究適應的擴大
  • 特別藥的指定
  • 癌症相關意識的高漲

第12章 業者情勢

  • 概要
  • 創造性破壞狀況

第13章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • 小野藥品工業

第14章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第15章 關於TECHNAVIO

目錄
Product Code: IRTNTR31971

About this market

Technavio's CTLA4 (Cytotoxic T-Lymphocyte-Alymphocyte-associated Protein 4) inhibitors market analysis considers sales from both monotherapy and combination therapy . Our analysis also considers the sales of CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) inhibitors in Asia, Europe, North America, and ROW. In 2018, the monotherapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as low side effects due and better tolerability will play a significant role in the monotherapy segment to maintain its market position. Also, our global CTLA4 inhibitors market report looks at factors such as high target affinity and specificity of CTLA4 inhibitors, growing popularity of combination therapy, and strategic alliances. However, lack of approved therapies, availability of substitutes, and stringent regulations may hamper the growth of the CTLA4 (Cytotoxic T-Lymphocyte-Alymphocyte-associated Protein 4) inhibitors industry over the forecast period.

Overview

High target affinity and specificity of CTLA4 inhibitors

CTLA4 inhibitors function by boosting the immune system and reducing the side effects. CTLA-4 is a protein found on the surface of T-cells which suppress the growth of cancer cells by activating the immune system. These drugs work directly on the target, and their efficacy is higher than that of other conventional treatments such as chemotherapy. Though the CTLA4 inhibitors are new to the oncology treatment landscape, increasing R&D efforts by market vendors are supporting the growth of CTLA4 inhibitors market This will lead to the expansion of the global CTLA4 inhibitors market at a CAGR of over 9% during the forecast period.

Increasing awareness about cancer

The awareness programs conducted by various organizations provide an opportunity to raise awareness about lung cancer screening and treatment options, including CTLA4 inhibitors. For instance, Cancer Breakthroughs 2020 an initiative taken by the US government for the development of research on vaccine-based immunotherapies for cancer. This project aimed at making therapies available to more patients while detecting the disease at an early stage. Such awareness programs are also raising awareness about the treatment of various cancer types by using CTLA4 inhibitors. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global CTLA4 (Cytotoxic T-Lymphocyte-Alymphocyte-associated Protein 4) inhibitors market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of a few major players, the global CTLA4 inhibitors market is highly concentrated. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading CTLA4 inhibitors manufacturers, that include AstraZeneca Plc, Bristol-Myers Squibb Co., Ono Pharmaceutical Co. Ltd.

Also, the CTLA4 (Cytotoxic T-Lymphocyte-Alymphocyte-associated Protein 4) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Monotherapy - Market size and forecast 2018-2023
  • Combination therapy - Market size and forecast 2018-2023
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Expansion of research indications
  • Special drug designations
  • Increasing awareness about cancer

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co.
  • Ono Pharmaceutical Co. Ltd.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Type - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by type
  • Exhibit 20: Monotherapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Monotherapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Combination therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Combination therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by type
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Key leading countries
  • Exhibit 37: Market opportunity
  • Exhibit 38: Impact of drivers and challenges
  • Exhibit 39: Vendor landscape
  • Exhibit 40: Landscape disruption
  • Exhibit 41: Vendors covered
  • Exhibit 42: Vendor classification
  • Exhibit 43: Market positioning of vendors
  • Exhibit 44: AstraZeneca Plc - Vendor overview
  • Exhibit 45: AstraZeneca Plc - Business segments
  • Exhibit 46: AstraZeneca Plc - Organizational developments
  • Exhibit 47: AstraZeneca Plc - Geographic focus
  • Exhibit 48: AstraZeneca Plc - Key offerings
  • Exhibit 49: AstraZeneca Plc - Key customers
  • Exhibit 50: Bristol-Myers Squibb Co. - Vendor overview
  • Exhibit 51: Bristol-Myers Squibb Co. - Business segments
  • Exhibit 52: Bristol-Myers Squibb Co. - Organizational developments
  • Exhibit 53: Bristol-Myers Squibb Co. - Geographic focus
  • Exhibit 54: Bristol-Myers Squibb Co. - Key offerings
  • Exhibit 55: Bristol-Myers Squibb Co. - Key customers
  • Exhibit 56: Ono Pharmaceutical Co. Ltd. - Vendor overview
  • Exhibit 57: Ono Pharmaceutical Co. Ltd. - Business segments
  • Exhibit 58: Ono Pharmaceutical Co. Ltd. - Organizational developments
  • Exhibit 59: Ono Pharmaceutical Co. Ltd. - Geographic focus
  • Exhibit 60: Ono Pharmaceutical Co. Ltd. - Key offerings
  • Exhibit 61: Ono Pharmaceutical Co. Ltd. - Key customers
  • Exhibit 62: Validation techniques employed for market sizing
  • Exhibit 63: Definition of market positioning of vendors